Relmada (NASDAQ: RLMD) is a late-stage biotech company focused upon addressing diseases of the central nervous symptom (CNS) in an entirely new way. Our lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for the adjunctive treatment of major depressive disorder (MDD). Data from the Phase 2 trial with REL-1017 suggest rapid and sustained antidepressant effects with statistically significant improvements as compared to placebo on all measured efficacy measures. The Phase 2 study data also suggest a favorable safety and tolerability profile of REL-1017 relative to placebo-treated patients on a background of anti-depressant therapy (ADT). The U.S. Food and Drug Administration has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. RELIANCE-I, the first pivotal trial, was initiated in December 2020, and Relmada announced that RELIANCE-II and RELIANCE-OLS were underway in April 2021.